- Home
- RNAZ vs PAPL Comparison
RNAZ vs PAPL Comparison
Compare RNAZ & PAPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- PAPL
- Stock Information
- Founded
- RNAZ 2016
- PAPL 2015
- Country
- RNAZ United States
- PAPL Canada
- Employees
- RNAZ N/A
- PAPL N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- PAPL Finance: Consumer Services
- Sector
- RNAZ Health Care
- PAPL Finance
- Exchange
- RNAZ Nasdaq
- PAPL Nasdaq
- Market Cap
- RNAZ 4.9M
- PAPL 4.4M
- IPO Year
- RNAZ 2021
- PAPL 2023
- Fundamental
- Price
- RNAZ $3.84
- PAPL $0.48
- Analyst Decision
- RNAZ Strong Buy
- PAPL Strong Buy
- Analyst Count
- RNAZ 1
- PAPL 1
- Target Price
- RNAZ $20.00
- PAPL $5.50
- AVG Volume (30 Days)
- RNAZ 69.9K
- PAPL 66.7K
- Earning Date
- RNAZ 11-14-2024
- PAPL 01-14-2025
- Dividend Yield
- RNAZ N/A
- PAPL N/A
- EPS Growth
- RNAZ N/A
- PAPL N/A
- EPS
- RNAZ N/A
- PAPL N/A
- Revenue
- RNAZ N/A
- PAPL $2,535,718.00
- Revenue This Year
- RNAZ N/A
- PAPL $38.59
- Revenue Next Year
- RNAZ $233.33
- PAPL $61.76
- P/E Ratio
- RNAZ N/A
- PAPL N/A
- Revenue Growth
- RNAZ N/A
- PAPL N/A
- 52 Week Low
- RNAZ $3.21
- PAPL $0.41
- 52 Week High
- RNAZ $264.00
- PAPL $2.14
- Technical
- Relative Strength Index (RSI)
- RNAZ 23.15
- PAPL 38.53
- Support Level
- RNAZ $6.63
- PAPL $0.41
- Resistance Level
- RNAZ $8.46
- PAPL $0.51
- Average True Range (ATR)
- RNAZ 1.04
- PAPL 0.04
- MACD
- RNAZ -0.25
- PAPL 0.00
- Stochastic Oscillator
- RNAZ 1.65
- PAPL 32.61
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About PAPL Pineapple Financial Inc.
Pineapple Financial Inc is a Canada-based mortgage technology and brokerage company that provides mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. Through its data-driven systems together with cloud-based tools, it offers advantages in the Canadian mortgage industry relative to alternative mortgage broker arrangements and also provides back office services.